Myriad Genetics, Illumina achieve milestones in strategic partnership

Myriad Genetics (MYGN) announced two key milestones in its strategic partnership with Illumina Inc. (ILMN) to advance and support clinical research for gene-based, targeted therapies. Under the strategic partnership, Myriad and Illumina are working together to advance comprehensive genomic profiling plus homologous recombination deficiency testing using the globally distributed Illumina TruSight Oncology 500 assay, which enables comprehensive genomic profiling by analyzing 523 genes across DNA and RNA variants. The first milestone achieved qualifies Myriad to conduct prospective clinical trial testing with an investigational use only test based off of Illumina’s in-development IVD solution, TruSight Oncology Comprehensive test. This positions Myriad to partner with leading pharmaceutical companies and academic institutions to further development of companion diagnostics. The second milestone involves Myriad’s initiation of its first reproducibility test project to support future regulatory filings for TSO Comp. Myriad now provides support in Illumina’s partnerships with pharmaceutical companies to develop companion diagnostics on TSO Comp.